MedTrace Logo

Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

NCT06948955 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this expanded access program (EAP) is to provide investigational bezuclastinib so that it can be coadministered with sunitinib to patients with a diagnosis of gastrointestinal stromal tumors (GIST) with no comparable or satisfactory alternative therapy options. The combination of bezuclastinib and sunitinib provides broad inhibition of all primary and secondary KIT mutations that commonly occur in GIST.

Conditions

  • Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Interventions

DRUG

Bezuclastinib

Drug: Bezuclastinib

DRUG

Sunitinib

Drug: Sunitinib (locally sourced)

Sponsors & Collaborators

  • Cogent Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Rachael Easton, MD, PhD · Cogent Biosciences, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06948955 on ClinicalTrials.gov